Dr. Theresa Mullin to Join CDER
Theresa Mullin, PhD, will join CDER on September 24, 2007, as the associate director for analysis and strategic initiatives.
Theresa Mullin, PhD, will join CDER on September 24, 2007, as the associate director for analysis and strategic initiatives. As associate director, she will lead CDER’s long-range planning and strategic modernization initiatives.
Mullin previously worked as the assistant commissioner for planning and as director of the office of planning in the office of the commissioner. As chief planner, she led the development of the FDA’s strategic action plans and performance plans that were incorporated into agency budget requests. Mullin played a role in establishing the FDA Bioinformatics Board and provided early support for the FDA critical path initiative. Prior to her work at the FDA, Mullin worked as a principal scientist with the Decision Science Consortium, and as senior manager with the Lewin Group.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
